

## Special Issue

# Advanced Concepts in Vaccines in Public Health

### Message from the Guest Editors

For decades, vaccines have been a crucial instrument for preventing infectious diseases. New vaccines are being developed and tested for the control of emerging diseases, such as COVID-19, Dengue fever, and RSV, including mRNA vaccines to prevent several high-burden infectious diseases (e.g., HIV, Hepatitis C, Malaria, etc.). As research progresses, the urgent need for data on the efficacy, effectiveness, and safety of these vaccines in specific population subsets increases. Novel articles, summaries, and reviews are encouraged for this Special Issue that may contribute new information on advanced concepts on the efficacy, safety, and cost-effectiveness of the vaccines, leading to more advanced and tailored public health strategies.

### Guest Editors

Prof. Dr. Lamberto Manzoli

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy

Prof. Dr. Maria Elena Flacco

Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy

### Deadline for manuscript submissions

30 November 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/205608](https://mdpi.com/si/205608)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).